Copyright
©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jan 14, 2016; 22(2): 874-886
Published online Jan 14, 2016. doi: 10.3748/wjg.v22.i2.874
Published online Jan 14, 2016. doi: 10.3748/wjg.v22.i2.874
Hepatocyte transplantation program: Lessons learned and future strategies
Eugenia Pareja Ibars, Laia Tolosa, Slivia López, Maria Jose Gomez-Lechón, Jose Vicente Castell, Jose Mir, Unidad de Terapia Celular Hepatica, Instituto de Investigación Sanitaria La Fe, Hospital Universitario y Politécnico La Fe de Valencia, 46026 Valencia, Spain
Eugenia Pareja Ibars, José Mir, Unidad de Cirugía Hepato-Bilio-Pancreática y Trasplante Hepático, Hospital Universitario y Politécnico La Fe de Valencia, 46026 Valencia, Spain
Miriam Cortes, Liver transplantation, Institute of Liver Studies, King’s College Hospital, Institute of Liver Studies, SE5 9RS London, United Kingdom
Maria José Gómez-Lechón, Unidad de Hepatologıa Experimental, Instituto de Investigación Sanitaria La Fe, Hospital Universitario y Politécnico La Fe de Valencia, 46026 Valencia, Spain
Maria José Gómez-Lechón, José Vicente Castell, CIBERehd, FIS, 08036 Barcelona, Spain
Author contributions: Ibars EP and Cortes M wrote the paper; Cortes M and Tolosa L made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; Gómez-Lechón MJ, Castell JV and Mir J contributed drafting the article or revising it critically for important intellectual content.
Conflict-of-interest statement: The authors have not conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Eugenia Pareja Ibars, MD, PhD, Hepatobiliary and liver Transplant Surgeon, Unidad de Cirugía Hepato-Bilio-Pancreática y Trasplante Hepático, Hospital Universitario y Politécnico La Fe de Valencia, Torre F, 5ª Planta, Avenida Fernando Abril Martorell 106, 46026 Valencia, Spain. pareja_eug@gva.es
Telephone: +34-961-245858 Fax: +34-961-246240
Received: April 28, 2015
Peer-review started: May 6, 2015
First decision: June 2, 2015
Revised: July 29, 2015
Accepted: November 30, 2015
Article in press: December 1, 2015
Published online: January 14, 2016
Processing time: 252 Days and 21.3 Hours
Peer-review started: May 6, 2015
First decision: June 2, 2015
Revised: July 29, 2015
Accepted: November 30, 2015
Article in press: December 1, 2015
Published online: January 14, 2016
Processing time: 252 Days and 21.3 Hours
Core Tip
Core tip: Our aim is to share the lessons learned over time during the establishment of the hepatocyte transplantation (HT) program at our hospital and to envisage future strategies. The hepatocyte isolation and cryopreservation procedures have been optimized and, fast and sensitive criteria for assessment of functionality of hepatocyte preparations and suitability for transplantation have been set up. Neonatal hepatocytes show high-functional quality and could improve cell therapy applicability. Our results (patients with acute liver failure and inborn metabolic diseases) indicate that HT could be a safe and efficient therapy, as long as viable and high-quality, metabolically functional human hepatocytes are available.